secwatch.observer — SEC 8-K summary
======================================

Issuer:     Immunome Inc. (IMNM)
CIK:        0001472012
Form:       8-K
Filed at:   2024-01-11T23:59:59+00:00
Accession:  0001104659-24-003380
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Immunome plans three INDs by 1Q 2025; closes Zentalis ADC license, Atreca antibody purchase
--------------------------------------------------------------------------------

- Zentalis ADC license: $35M upfront (cash+stock), $275M milestones, mid-to-high single digit royalties for ROR1 ADC IM-1021.
- Atreca antibody purchase: $5.5M cash upfront, $7M milestones for over 25 preclinical antibodies; closing subject to shareholder approval.
- IND filings planned for 1Q 2025 for FAP radioligand therapy, ROR1 ADC (IM-1021), and IL-38 immunotherapy.
- AbbVie collaboration: $30M upfront, up to $70M platform payments, $120M per target milestones, $150M per target sales milestones.
- Preclinical data shows IM-1021 superior to MK-2140 in TNBC model; proprietary payload outperforms Enhertu in HER2-low model.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1472012/000110465924003380/0001104659-24-003380-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1472012/000110465924003380/tm242340d3_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-003380

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer